Previous 10 | Next 10 |
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported recent business highlights, anticipated upcoming milestones, and financial results for the third quarter and first...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical data on its BTK inhibitor BRUKINSA ® (zanubrutinib) and non-clinical data on its anti-PD-1...
BioAtla and BeiGene (BGNE) have revised previously announced global co-development and commercialization agreement for former's BA3071, an investigational conditionally active CTLA-4 inhibitor designed to be conditionally activated in the tumor microenvironment in order to reduce sy...
BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biotechnology company, today announced that the two companies have revis...
Insider buying decreased last week. Notable Insider Buys: Continental Resources, Inc., Douglas Emmett, Inc., PBF Energy Inc., Phillips 66 Partners LP, Steelcase Inc. Notable Insider Sells: salesforce.com, inc., BeiGene, Ltd., Paycom Software, Inc., Morningstar, Inc., RealPage, Inc...
Leap Therapeutics (LPTX) up 7.2% in premarket, and BeiGene, (BGNE) have announced that first patient has been dosed in the DisTinGuish Phase 2a trial, evaluating Leap's DKN-01, in combination with latter's tislelizumab, with or without chemotherapy in patients with gastric...
Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer PR Newswire CAMBRIDGE, Mass. and BEIJING, Sept. 21, 2020 CAMBRIDGE, Mass. an...
When it comes to astronomical returns in investing, one of the most important factors -- aside from buying the right company -- is buying your shares early, when ordinary people have never heard of the stock. Of course, there is a danger in being too early. But you can guard against that dange...
BeiGene (NASDAQ: BGNE ) announces the first reported data from RATIONALE 304 , the Phase 3 trial of its anti-PD-1 antibody tislelizumab in combination with chemotherapy as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NS...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the first reported data from RATIONALE 304, the Phase 3 trial of its anti-PD-1 antibody tislelizumab in combination wit...
News, Short Squeeze, Breakout and More Instantly...
BeiGene Ltd. Company Name:
BGNE Stock Symbol:
NASDAQ Market:
Study evaluating BRUKINSA ® in combination with venetoclax in high-risk, treatment-naïve CLL/SLL patients to be shared as oral presentation BCL2 inhibitor sonrotoclax subject of multiple presentations highlighting promising safety and efficacy as monotherapy and in c...
Total revenues of $752 million in the first quarter, including product revenue of $747 million, an 82% increase from the prior-year period BRUKINSA revenue of $489 million, driven by growth in the U.S. and Europe of 153% and 243%, respectively, from the prior-year period; with recent fift...